Therapeutic Solutions International Inc (TSOI)

[BigBadWolf]

Dixon Releases 80PRs 12/01/20- 12/05/22 Undisclosed Consultant Campaign
appears he knows all about pumps & ________s
Therapeutic Solutions International Announces Improvements in Autism, Amyotrophic Lateral Sclerosis and Schizophrenia Cases Treated by Veltmeyer Institute for Advanced Therapeutics
Business WireMon, Dec. 05, 2022
Therapeutic Solutions International Granted Broad Patent on Treatment of Neurodegenerative Conditions
Business WireMon, Nov. 28, 20221 Comment
Therapeutic Solutions Announces Universal Donor Myeloid Derived Suppressor Therapy Platform for Treatment of Chronic Obstructive Pulmonary Disease (COPD)
Business WireMon, Nov. 14, 2022
Therapeutic Solutions International Launches Spin-Off Breathe Biologics Aimed at Curing Chronic Obstructive Pulmonary Disease (COPD)
Business WireWed, Nov. 09, 2022
Therapeutic Solutions International Spin-Off Res Nova Bio Collaborates with Veltmeyer MD Inc. to Provide Breast Cancer Patients Access to Novel Cancer Immunotherapy
Business WireMon, Nov. 07, 2022
Therapeutic Solutions International Announces Launch of Cancer Immunotherapy Spin-Off Res Nova Bio, Inc.
Business WireThu, Oct. 27, 2022
Therapeutic Solutions International Announces Successful Treatment of Epilepsy in Animal Model and Complete Cessation of Seizures in Treatment Resistant Patient
Business WireMon, Oct. 24, 2022
Therapeutic Solutions International Granted Landmark United States Patent on Ability of QuadraMune® Nutraceutical to Repair Injured Brains
Business WireMon, Oct. 10, 2022
Therapeutic Solutions International Identifies CD103 Expressing Dendritic Cells and Exosomes Thereof as Novel Mechanism for JadiCell Mesenchymal Stem Cell Mediated Lung Protection
Business WireMon, Oct. 03, 2022
Therapeutic Solutions International Secures Financing to Complete Current Phase III Stem Cell Clinical Trial
Business WireTue, Sep. 20, 2022
Therapeutic Solutions International Spin-Off Company Campbell Neurosciences Announces Successful Preclinical Studies of CampbellCell for Treatment of Bipolar Disorder
Business WireMon, Sep. 19, 2022
Therapeutic Solutions International Develops Post JadiCell Maintenance Therapy for Chronic Obstructive Pulmonary Disease (COPD)
Business WireMon, Sep. 12, 2022
Therapeutic Solutions International Develops Gene Silencing Therapy for Acute Respiratory Distress Syndrome
Business WireMon, Aug. 29, 2022
Therapeutic Solutions International Files with FDA to Expand ongoing Phase III Clinical Trial to Include All Causes of Acute Respiratory Distress Syndrome
Business WireThu, Aug. 25, 2022
Therapeutic Solutions International Reports Superior Efficacy of ApoptoCyte™ on Chronic Obstructive Pulmonary Disease Model Compared to Conventional Stem Cell Approaches
Business WireFri, Aug. 12, 2022
Therapeutic Solutions International Creates Disease Specific Therapeutic Platform Based on Gene Editing/Engineering of Inducible Pluripotent Stem Cells
Business WireThu, Jul. 28, 2022
Therapeutic Solutions International Announces Initiation of JadiCell™ Manufacturing Program to Address Upcoming FDA Phase III Trial and Emergency Use Requests
PR NewswireMon, Oct. 11, 2021
Therapeutic Solutions International Utilizes Mesenchymal Stem Cell Exosomes to Effectively Suppress Neutrophil Extracellular Trap Production
PR NewswireMon, Oct. 04, 20212 Comments
Therapeutic Solutions International Discusses Claims of Possible COVID-19 Suppressive Activity of QuadraMune™ Ingredients by Independent Universities Made After Patent Filing
PR NewswireMon, Sep. 27, 2021
Therapeutic Solutions International Discovers and Files Patent on Novel Cellular Therapy Combination for Augmentation of Lung Repair in COVID-19 Model
PR NewswireWed, Sep. 22, 2021
Therapeutic Solutions International Identifies and Files Patent on Combination Effects Between its Nutraceutical QuadraMune™ and Ivermectin in Animal Models of COVID-19 Pathology
PR NewswireThu, Sep. 16, 2021
Therapeutic Solutions International Successfully Treats Veteran Navy SEAL Suffering from Chronic Traumatic Encephalopathy with JadiCell™ Adult Stem Cells Under Right to Try Law
PR NewswireMon, Sep. 13, 2021
Therapeutic Solutions International Engages Venvalo Group to Oversee JadiCell COVID-19 Phase III Clinical Trial and Emergency Use Authorization (EUA) Process
PR NewswireFri, Sep. 10, 2021
Therapeutic Solutions International Signs Memorandum of Understanding with Clinical Stage Immunotherapy Company Eutilogics, Inc. to Explore Augmentation of Synergies between StemVacs-V and TAST
PR NewswireTue, Sep. 07, 2021
Therapeutic Solutions International Files Investigational New Drug Application with FDA for Cancer Blood Vessel Targeting Immunotherapy StemVacs-V to Treat Metastatic Breast Cancer
PR NewswireMon, Aug. 30, 2021
Therapeutic Solutions International Recruits Internationally Renowned Stem Cell Pioneer Francisco Silva to Scientific Advisory Board
PR NewswireThu, Aug. 26, 2021
Therapeutic Solutions International Announces Positive Preclinical Results Using JadiCells™ in Animal Model of Chronic Obstructive Pulmonary Failure (COPD)
PR NewswireMon, Aug. 23, 2021
Therapeutic Solutions International Announces Titan of Industry Dr. Peter Farrell Joins Advisory Board of its Suicide Prevention Spin-Off Campbell Neurosciences
PR NewswireFri, Aug. 20, 2021
Therapeutic Solutions International Recruits Pharmaceutical Industry Veteran Dr. Boris Reznik to Accelerate Value Optimization of FDA Cleared Phase III COVID JadiCell™ Clinical Trial
PR NewswireThu, Aug. 19, 2021
Therapeutic Solutions International Identifies and Files Patent on Novel Mechanism of Action of Its FDA Phase III Cleared JadiCell™ Treatment of COVID-19 and Delta Variant
PR NewswireWed, Aug. 18, 2021
Therapeutic Solutions International Prepares to Apply for Emergency Use Authorization (EUA) for its FDA Phase III COVID-19 Stem Cell Therapy JadiCell™
PR NewswireMon, Aug. 16, 2021
Therapeutic Solutions International Reports Superior Neurogenesis Induction in Animal Model of Viral Induced Cognitive Dysfunction Compared to other Stem Cell Types
PR NewswireWed, Aug. 11, 2021
Therapeutic Solutions International Completes FDA Requested Studies to Initiate JadiCell™ Chronic Traumatic Encephalopathy (CTE) Clinical Trial
PR NewswireMon, Aug. 09, 2021
Therapeutic Solutions International Receives FDA Clearance to Initiate Phase III Pivotal Registration Trial for JadiCell™ Universal Donor COVID-19 Therapy
PR NewswireThu, Aug. 05, 2021
Therapeutic Solutions International Reports Preclinical Efficacy of JadiCell Umbilical Cord Mesenchymal Stem Cells in Animal Model Resembling COVID-19 Delta Variant Associated Lung Pathology
PR NewswireTue, Jul. 27, 2021
Therapeutic Solutions International Spin-Off Campbell Neurosciences Explains Why Suicide is a Disease and How to Predict it in Newly Released Video
PR NewswireThu, Jul. 08, 2021
Therapeutic Solutions International Patents Modified StemVacs Dendritic Cell Immunotherapy to Suppress Parkinson's Disease in Animal Model
PR NewswireTue, Jul. 06, 2021
Therapeutic Solutions International Spin-Off Campbell Neurosciences Initiates Pilot Implementation of Campbell Score™ with California Concierge Medical & Wellness Inc.
PR NewswireFri, Jul. 02, 2021
Therapeutic Solutions International Demonstrates Potent Brain Protective Activity of JadiCells in Animal Model of Post-Covid-19 Neurological Damage
PR NewswireWed, Jun. 30, 2021
Campbell Neurosciences Spin Off of Therapeutic Solutions Reports Synergistic Reduction of Schizophrenia in Animal Models using Low Dose Naltrexone and T Regulatory Cell Stimulation
PR NewswireWed, Jun. 16, 2021
Therapeutic Solutions International Spinoff Campbell Neurosciences Reports Reduction of Schizophrenia Activity in Mice Subsequent to Administration of Tolerogenic Dendritic Cells
PR NewswireThu, Jun. 10, 2021
Therapeutic Solutions International Reports Amplification of Cancer Specific Immune Responses Using Second Generation Tumor Endothelial Targeting Vaccine StemVacs-V iPSC
PR NewswireMon, Jun. 07, 2021
Therapeutic Solutions International Subsidiary Campbell Neurosciences Identifies T Regulatory Cells as a Mechanism of Stem Cell Suppression of Schizophrenia Pathology in an Animal Model
PR NewswireWed, Jun. 02, 2021
Therapeutic Solutions International Optimizes Targeting the "Achilles Heel" of Cancer Using Second Generation Tumor Endothelial Targeting Vaccine StemVacs-V iPSC
PR NewswireMon, May 24, 2021
Therapeutic Solutions International Develops Novel Stem Cell Based Therapy to Reduce Lung Scarring: Potential Solution to Post COVID-19 Lung Deterioration
PR NewswireFri, May 21, 20212 Comments
Therapeutic Solutions International Spin-Off Campbell Neurosciences Recruits Global Dealmaker Kenji Funahashi to Advisory Board
PR NewswireWed, May 19, 2021
Therapeutic Solutions International and Campbell Neurosciences Announce Preclinical Studies Showing Low Doses of FDA Cleared Immune Stimulant Interleukin-2 Reduces Inflammation Associated Depression in Animal Model
PR NewswireMon, May 17, 2021
Therapeutic Solutions International Subsidiary Campbell Neurosciences Reports Positive Preclinical Data in Animal Model of Schizophrenia Using Proprietary Universal Donor Mesenchymal Stem Cell
PR NewswireMon, May 10, 2021
Therapeutic Solutions International Comes to Agreement with FDA on Clinical Trial Design for First Stem Cell Clinical Trial in Chronic Traumatic Encephalopathy (CTE) Patients
PR NewswireFri, Apr. 30, 2021
Therapeutic Solutions International Reports Regression of Established Tumors by Combining its Cancer Blood Vessel Targeting Immunotherapy with Low Dose Chemotherapy
PR NewswireMon, Apr. 26, 2021
Therapeutic Solutions International Spin-Off Campbell Neurosciences Identifies Mechanism of Action for Umbilical Cord Blood Derived NarcoStem™ Drug Rehabilitation Product
PR NewswireMon, Apr. 19, 2021
Therapeutic Solutions International with Subsidiary Campbell Neurosciences Develops Cord Blood Based Inhalable Product for Opioid Addiction
PR NewswireTue, Apr. 13, 2021
Therapeutic Solutions International Spin-Off Campbell Neurosciences Demonstrates Efficacy of Kaihani Score in Prediction of Gambling Addiction
PR NewswireMon, Apr. 05, 2021
Therapeutic Solutions International Demonstrates Potent and Selective Destruction of Tumor Blood Vessels by Leveraging Pre-Existing Natural Anti-Xenogeneic Antibodies
PR NewswireMon, Mar. 29, 2021
Therapeutic Solutions International Creates Hybrid Cell Designed to Educate Immune System to Choke Cancer Blood Vessels
PR NewswireTue, Mar. 23, 2021
Therapeutic Solutions International Announces Immunological Mechanism of Action of StemVacs-V™ iPSC Derived Cancer Immunotherapeutic
PR NewswireMon, Mar. 22, 2021
Therapeutic Solutions International Announces Novel Cancer-Resistant iPSC-Derived Dendritic Cell Immunotherapy: StemVacs-V™
PR NewswireTue, Mar. 16, 2021
Therapeutic Solutions International Spin-off Campbell Neurosciences Announces Umbilical Cord Derived Monocyte Immunotherapy Candidate for Suicide Prevention
PR NewswireThu, Mar. 04, 2021
Therapeutic Solutions International Approved on RangeMe to sell QuadraMune™ and NanoStilbene™ along with other supplements
PR NewswireWed, Mar. 03, 2021
Therapeutic Solutions International Approved by Amazon to sell its highly regarded immune supplement QuadraMune™ along with other brands.
PR NewswireFri, Feb. 26, 2021
Therapeutic Solutions International Spin-Off Campbell Neurosciences Demonstrates Preliminary Efficacy of First Blood-Based Test for Gambling Addiction: Kaihani Score™
PR NewswireThu, Feb. 25, 2021
Therapeutic Solutions International Uses StemVacs™ Platform to Generate Personalized Adoptive T Cell Therapy Targeting Cancer Stem Cells
PR NewswireMon, Feb. 22, 2021
Therapeutic Solutions International Spin-Off Campbell Neurosciences Announces Positive Clinical Trial Results for Campbell Score Blood Based Suicide Prediction
PR NewswireThu, Feb. 18, 2021
Therapeutic Solutions International Appoints Internationally Renowned Tumor Immunologist Dr. Boris Minev to its Scientific Advisory Board
PR NewswireTue, Feb. 16, 2021
Therapeutic Solutions International Acquires Stem Cell Therapy That Successfully Completed FDA Double Blind Placebo Controlled Efficacy Study for Lung Disease
PR NewswireWed, Feb. 10, 2021
Therapeutic Solutions International Reports Preliminary Data Suggesting StemVacs Induces Natural Killer Memory to Cancer
PR NewswireMon, Feb. 08, 2021
Therapeutic Solutions International Enters into Master Sales Agreement with Community Shield LLC
PR NewswireThu, Feb. 04, 2021
Therapeutic Solutions International Reports Therapeutic Efficacy of StemVacs Derived Exosomes in Regression of Glioma
PR NewswireMon, Feb. 01, 2021
Therapeutic Solutions International Reports Enhancement of StemVacs Immune Stimulating Activity Using Neuromodulatory Compound Homotaurine
PR NewswireTue, Jan. 26, 2021
Therapeutic Solutions International Reports Regression of Glioma, Lung Cancer and Colorectal Cancer using StemVacs in Animal Models
PR NewswireMon, Jan. 25, 2021
Therapeutic Solutions International Reports Successful Treatment of Breast Cancer using StemVacs™ Cellular Immunotherapy
PR NewswireTue, Jan. 19, 2021
Therapeutic Solutions International Announces Positive Early Clinical Data from Ongoing Suicidal Ideation Blood Biomarker Clinical Trial with Spinoff Campbell Neurosciences
PR NewswireWed, Jan. 13, 2021
Therapeutic Solutions International Reports QuadraMune™ Administration Enhances T Cytotoxic Responses in Mouse Model of Adaptive Immunity
PR NewswireTue, Jan. 05, 2021
Therapeutic Solutions International Launches Campbell Neurosciences Inc as First Suicide Focused Regenerative Psychiatry Biotechnology Company
PR NewswireThu, Dec. 31, 2020
Therapeutic Solutions International Reports QuadraMune™ Increases T Cell Immunity in Animal Studies
PR NewswireWed, Dec. 30, 2020
Therapeutic Solutions International Files Patent on NeuroLeukin™ Personalized Immunotherapy for Opioid Addiction
PR NewswireMon, Dec. 21, 2020
Therapeutic Solutions International Files Investigational New Drug Application (IND) with FDA for Treatment of Chronic Traumatic Encephalopathy Using Clinically Validated JadiCell® Universal Donor Stem Cell
PR NewswireThu, Dec. 17, 2020
Therapeutic Solutions International Signs Letter of Intent with Premier Adipose Stem Cell Company Synova Life Sciences to File IND for Suicide Prevention
PR NewswireWed, Dec. 16, 2020
Therapeutic Solutions International Division of Campbell Neurosciences Files Patent on QuadraMune™ for Treatment of Major Depressive Disorder
PR NewswireWed, Dec. 09, 2020
Therapeutic Solutions International Announces Clinical Trial Assessing "Kaihani Score" Proprietary Biomarker Based Assay for Quantifying Gambling Addiction
PR NewswireWed, Dec. 02, 2020
Therapeutic Solutions International Announces Positive QuadraMune™ Clinical Trial Data
PR NewswireTue, Dec. 01, 2020

https://seekingalpha.com/symbol/TSOI/press-releases